** Medical device maker Medtronic's MDT.N shares rise 1% to $90.86

** U.S. FDA has approves co's deep brain stimulation system $(DBS)$ for use in patients with Parkinson's disease

** DBS uses a surgically implanted device called neurostimulator to send electrical signals to specific parts of the brain that have been affected by the neurological disorder

** The system adjusts the therapy to each person's brain activity in real time

** The tech will be available to Parkinson's patients who have been previously implanted with a neurostimulator, as well as future DBS patients - co

** Patient programmings in the United States will begin at select healthcare systems over the coming weeks with availability nationwide in the coming months - MDT

** MDT rose 4.7% in the last 12 months

(Reporting by Siddhi Mahatole)

((Siddhiprabhanjan.mahatole@thomsonreuters.com))